How should hyperplastic gastric polyps be managed, including indications for removal, biopsy, H. pylori testing, and follow‑up?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Hyperplastic Gastric Polyps

All hyperplastic gastric polyps should be biopsied for histological confirmation, tested for H. pylori, and polyps >1 cm, pedunculated polyps, or symptomatic polyps should be completely resected—but only after H. pylori eradication is attempted first, as up to 70% will regress spontaneously. 1

Initial Diagnostic Approach

When hyperplastic polyps are identified:

  • Document the number (or estimated number if numerous), location, size of largest polyp, and morphology with photographic documentation 1
  • Biopsy all hyperplastic polyps to confirm diagnosis and exclude dysplasia (1.9-19% harbor dysplasia) 1
  • Systematically evaluate the background mucosa for gastric atrophy (GA), gastric intestinal metaplasia (GIM), and synchronous neoplasia—hyperplastic polyps are associated with these conditions in approximately 6% of cases 1

Key Clinical Context

Hyperplastic polyps constitute 18-70% of all gastric polyps, are typically single or few in number, and appear as smooth, red, dome-shaped lesions with whitish exudates (fibrin). They're most commonly found in the antrum or adjacent to ulcers, stomas, and gastrectomy sites 1. The malignant transformation risk is particularly elevated when polyps are >1 cm or in postgastrectomy stomachs 1.

H. Pylori Testing and Eradication

Test all patients with hyperplastic polyps for H. pylori using histology, immunohistochemistry, or urea breath testing 1, 2. This is critical because:

  • 25% of hyperplastic polyps are associated with H. pylori gastritis 1
  • Up to 70% of hyperplastic polyps regress after H. pylori eradication 1, 3
  • Eradication should be attempted before endoscopic resection 1

Perform repeat endoscopy 3-6 months after successful eradication to reassess polyp status 1. This strategy can avoid unnecessary polypectomy in the majority of cases.

Indications for Resection

Complete endoscopic resection is indicated for:

  1. Polyps >1 cm (high dysplasia/cancer risk) 1
  2. Pedunculated morphology 1
  3. Symptomatic polyps causing obstruction or bleeding 1
  4. Polyps >3 cm should always be resected regardless of H. pylori status due to very high dysplasia/cancer risk 1

Important caveat: Even when H. pylori is present, polyps >3 cm require immediate resection rather than waiting for post-eradication regression 1.

Surveillance Strategy

Surveillance intervals depend on histopathological findings:

If Dysplasia is Found in the Polyp:

  • High-grade dysplasia with complete resection: Follow-up endoscopy in 6 months 2
  • Low-grade dysplasia with complete resection: Follow-up endoscopy in 1 year 2
  • High-grade dysplasia with incomplete resection/biopsy only: Follow-up in 3 months 2
  • Low-grade dysplasia with incomplete resection/biopsy only: Follow-up in 6 months 2

If Background Mucosa Shows GA or GIM:

Endoscopic surveillance is recommended to monitor for gastric neoplasia risk 1. The surveillance interval should be determined by the stage of chronic atrophic gastritis present 1. This typically means surveillance every 3 years for extensive GIM per the 2025 AGA guidelines 4.

If No Dysplasia and No Significant Background Pathology:

No specific surveillance for the polyps themselves is required after complete resection, though the 2019 BSG guidelines suggest ongoing surveillance when appropriate based on individual risk factors 1.

Common Pitfalls to Avoid

  1. Don't resect before attempting H. pylori eradication in smaller polyps—you'll miss the opportunity for spontaneous regression in up to 70% of cases 1, 3

  2. Don't ignore the surrounding mucosa—approximately 6% of patients with dysplastic hyperplastic polyps have synchronous neoplastic lesions elsewhere 1

  3. Don't assume small polyps are benign—even polyps as small as 5 mm should be removed if they persist after H. pylori eradication, as dysplasia can occur in smaller lesions 5

  4. Don't forget to sample the background mucosa for GA, GIM, and H. pylori status—this determines long-term surveillance strategy 1

The evidence strongly supports a sequential approach: test and treat H. pylori first, reassess in 3-6 months, then resect persistent polyps meeting size/morphology criteria while carefully evaluating the surrounding mucosa for premalignant conditions that require ongoing surveillance.

Related Questions

How should gastric polyps be managed?
How should I explain to a patient with a hyperplastic gastric polyp containing intestinal metaplasia the need for H. pylori testing, eradication therapy (PPI plus amoxicillin and clarithromycin or metronidazole if penicillin‑allergic), repeat endoscopy in 3–6 months, possible polyp removal if >1 cm or symptomatic, and the follow‑up surveillance schedule?
How can I explain a hyperplastic gastric polyp, its cause (Helicobacter pylori infection), prognosis, and treatment options (including eradication therapy and endoscopic removal if indicated) to a patient?
What are the guidelines for managing a single prepyloric polyp identified on esophagogastroduodenoscopy (EGD)?
How should I manage an antral polyp in the setting of Helicobacter pylori infection?
In a patient with cerebellar symptoms and high anti‑RNP antibodies but a normal brain MRI, what is the recommended management?
What is the appropriate management for a 20‑month‑old child with an eyelid cyst present for one month?
When should a patient with statin‑induced myopathy start evolocumab (Repatha)?
Can metronidazole cause peripheral edema (leg swelling)?
For an adult with uncomplicated pyelonephritis who wishes to avoid fluoroquinolones due to Achilles tendon rupture risk, what are the recommended treatment options, including drug choice, dosage, and duration?
Is periodic PET/CT imaging medically necessary for a patient with stage IV breast cancer receiving ribociclib (Ibrance) and fulvestrant (Faslodex) after insurance denied coverage?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.